Ticker Details
Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.
IPO Date:	October 16, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$32.09M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.62 | 3.89%
Avg Daily Range (30 D):	$0.55 | 5.76%
Avg Daily Range (90 D):	$0.60 | 4.80%

Institutional Daily Volume
Avg Daily Volume:	.39M
Avg Daily Volume (30 D):	.49M
Avg Daily Volume (90 D):	.2M

Trade Size
Avg Trade Size (Sh.):	83
Avg Trade Size (Sh.) (30 D):	120
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	2,721
Avg Institutional Trade:	$2.22M
Avg Institutional Trade (30 D):	$.52M
Avg Institutional Trade (90 D):	$.52M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2M
Avg Closing Trade (30 D):	$4.55M
Avg Closing Trade (90 D):	$4.55M
Avg Closing Volume:	6.14K

News

Jan 30, 2025 @ 10:39 PM Wolf Haldenstein Adler Freeman & Herz LLP announce... Source: N/A

Nov 20, 2024 @ 9:47 PM FUJIFILM Diosynth Biotechnologies Celebrates the E... Source: Fujifilm Diosynth Biotechnologies

Jul 17, 2024 @ 11:03 AM Presenting on the Emerging Growth Conference 73 Da... Source: N/A

May 23, 2024 @ 2:06 PM Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease... Source: Zacks Equity Research

May 22, 2024 @ 3:12 PM GSK Studies on Depemokimab for Severe Asthma Meet ... Source: Zacks Equity Research

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$2.89	$-.32	$.2
Diluted EPS	$2.86	$-.32	$.19
Revenue	$151.93M	$3.45M	$17.58M
Gross Profit
Net Income / Loss	$23.4M	$-4.3M	$2.39M
Operating Income / Loss	$26.22M	$-3.57M	$3.2M
Cost of Revenue
Net Cash Flow	$-40.86M	$-11.16M	$2.92M
PE Ratio	0.00

Splits
Jun 20, 2024	1:25